Secondary hormonal manipulations in the treatment of castration refractory prostate cancer
K E T O C O N A Z O L E I N A D V A N C E D P R O S T A T E C A N C E R
2006, Edinburgh, Scotland: National
13 Taplin ME, Regan MM, Ko YJ et al.
Cancer Institute, 2009. Available at: http:/
22 Galsky MD, Simon K, Sonpavde G et al.
Ketoconazole retains activity in patients
Ferlay J, Parkin DM, Steliarova-Foucher
prostate cancer. Clin Cancer Res 2009;
cancer. Ann Oncol 2009; 20: 965-6 E. Estimates of cancer incidence and 15: 7099-105
23 Scholz M, Jennrich R, Strum S,
mortality in Europe in 2008. Eur J Cancer
14 Wilkinson S, Chodak G. An evaluation Brosman S, Johnson H, Lam R. Long-
2010; 46: 765-81 Touijer K, Scardino PT. Nomograms for
hormone refractory prostate cancer. Eur
independent prostate cancer treated with
Urol 2004; 45: 581-4
ketoconazole and hydrocortisone. J Urol
treatment outcomes. Cancer 2009; 115
15 Simon R. Optional two-stage designs for
2005; 173: 1947-52
phase II clinical trials. Control Clin Trials
24 Nakabayashi M, Xie W, Regan MM, Miyamoto H, Messing EM, Chang C.
1989; 10: 1-10 Jackman DM, Kantoff PW, Oh WK.
16 Armstrong AJ, Garrett-Mayer ES,
prostate cancer: current status and future
Yang YC, de Wit R, Tannock IF,
prospects. Prostate 2004; 61: 332-53 Eisenberger M. A contemporary Lam JS, Leppert JT, Vemulapalli SN,
independent prostate cancer. CancerShvarts O, Belldegrun AS. Secondary
2006; 107: 975-81
25 Nakabayashi M, Oh WK, Jacobus S et al.
cancer. J Urol 2006; 175: 27-34
analysis. Clin Cancer Res 2007; 13: Chaudhary UB, Rashid MH, Onitilo AA, Bissada NK. Secondary hormonal
17 Sternberg CN, Petrylak DP, Sartor O
resistant prostate cancer. BJU Int 2010;
et al. Multinational, double-blind, phase III 105: 1353-484
advanced prostate cancer. Can J Urol
study of prednisone and either satraplatin
2005; 12: 2666-76 Berthold DR, Pond GR, Soban F, de Wit
Fondazione Istituto Nazionale Tumori, Via G.
R, Eisenberger M, Tannock IF. Docetaxel
after prior chemotherapy: the SPARC trial.
J Clin Oncol 2009; 27: 5431-8
prednisone for advanced prostate cancer:
18 Loriot Y, Massard C, Gross-Goupil M et al. Combining carboplatin and J Clin Oncol 2008; 26: 242-5
Abbreviations: CRPC, castration-resistant Petrylak DP, Tangen CM, Hussain
prostate cancer; CR + PR + SD, complete HM et al. Docetaxel and extramustine
response + partial response + stable disease.
evaluating also neuroendocrine features.
Ann Oncol 2009; 20: 703-8
prostate cancer. N Engl J Med 2004; 351:
19 Danila DC, Morris MJ, de Bono JS et al.
Phase 2 multicenter study of abiraterone
EDITORIAL COMMENT Tannock IF, de Wit R, Berry WR et al.
patients with docetaxel treated castration
resistano prostate cancer. J Clin OncolMANIPULATIONS IN THE TREATMENT OF
prednisone for advanced prostate cancer.
2010; 28: 1496-501 CASTRATION REFRACTORY PROSTATE N Engl J Med 2004; 351: 1502-12
20 Sartor AO, Oudard S, Ozguroglu M
10 Pienta KJ, Bradley D. Mechanisms et al. Cabazitaxel or mitoxantrone with
The cornerstone of treatment for advanced
independent prostate cancer. Clin Cancer Res 2006; 15: 1665-71
castration i.e. androgen deprivation therapy
11 Madan RA, Lieberman R, Gulley J,
docetaxel: final results of a multinational
(ADT). Despite initial responses, almost all
Dahut W, Arlen PM. Significant
phase 3 trial. Proceedings of the American
prostate-specific antigen (PSA) response
prostate cancer (CRPC). In CRPC, most tumors
remain dependent on androgen receptor (AR)
Francisco. Pro ASCO GU 2010 abstract no.
signaling for proliferation  and many CRPC
independent prostate cancer (AIPC) and a
review of the literature. Am J Ther 2007;
21 Kantoff P, Higano CS, Berger ER et al. 14: 310-13
12 Reid AH, Attard G, Barrie E, de Bono JS.
In this paper, Procopio et al. report on the
for prostate cancer. Nat Clin Pract Urol
efficacy of low dose ketoconazole (200 mg
2008; 5: 610-20
orally every eight hours) in a phase 2, single
2 0 1 0 T H E A U T H O R SB J U I N T E R N A T I O N A L 2 0 1 0 B J U I N T E R N A T I O N A L
Higher baseline androstenedione levels were
Small EJ, Vogelzang NJ. Second-line
primary endpoint was PSA response, which
was defined as partial response (PR) i.e.
cancer: a shifting paradigm. J Clin Oncol
PSA ≤50% or complete response (CR) i.e.
ketoconazole (200 mg orally thrice daily) has
1997; 15: 382-8
undetectable PSA. There were two CRs and 6
also been shown to be associated with PSA
Nakabayashi M, Oh WK, Jacobus S et al.
PRs, with an overall PSA response rate of 21%.
These included one CR and four PRs in 15
patients with prior chemotherapy. However
resistant prostate cancer. BJU Int 2010;
the median duration of benefit was only 21
weeks (5 months) similar to prior reports of
Scher HI, Halabi S, Tannock I et al.
Design and end points of clinical trials for
signaling in disease progression in CRPC has
patients with progressive prostate cancer
It is of interest that 31 of 37 patients had
led to the development of newer drugs such
as abiraterone and MDV 3100. Abiraterone
acetate (Johnson & Johnson, New Brunswick,
Clinical Trials Working Group. J Clin Oncol
NJ), is an orally administered pregnenolone
2008; 26: 1148-59
meaning with respect to response, and has
analog that irreversibly inhibits CYP17 (a key
Chen Y, Clegg NJ, Scher HI. Anti-
been misconstrued as suggestive of clinical
enzyme in androgen synthesis) and blocks the
benefit . Therefore, the Prostate Cancer
synthesis of androgens in the testes, adrenal
Clinical Trials Working Group 2 (PCWG2) has
glands and prostate, without causing adrenal
insufficiency . MDV 3100 (Medivation Inc,
The Lancet Oncology 2009; 10:
San Francisco, CA) is an orally administered
maximal PSA decline/patient be reported in a
novel AR antagonist that binds to AR with a
Small EJ, Halabi S, Dawson NA et al.
waterfall plot. Waterfall plots allow a given
much higher affinity (eight times higher) than
data set to be analyzed on the basis of any
bicalutamide and blocks nuclear translocation
degree of decline and to be compared to other
promising results of phase 2 clinical trials,
patients: a phase III trial (CALGB 9583).
there are currently several ongoing phase 3
J Clin Oncol 2004; 22: 1025-33
Ketoconazole has a weak and non-specific
Nakabayashi M, Xie W, Regan MM,
inhibitory affect on several enzymes involved
patients with progressive CRPC, with results
Jackman DM, Kantoff PW, Oh WK.
in androgen synthesis and has been widely
expected in near future. Until more promising
used in combination with hydrocortisone for
ketoconazole remains a pertinent option in
ketoconazole is associated with significant
patients with CRPC when clinical trials are not
independent prostate cancer. Cancer
toxicities. The effect of ketoconazole on
2006; 107: 975-81
overall survival is difficult to discern . In a phase 3 study of 260 patients with CRPC, PSA
responses and ORs were significantly higher
Neeraj Agarwal* and Agarwal N, Hutson TE, Vogelzang NJ, Nicholas J. Vogelzang†,
hydrocortisone and antiandrogen withdrawal
Sonpavde G. Abiraterone acetate: a *University of Utah, Salt Lake City, UT, and
There was no difference in median survival
†Comprehensive Cancer Centers of Nevada,
(∼16 months for both arms of the study) .
Future Oncol 2010; 6: 665-79
B J U I N T E R N A T I O N A L 2 0 1 0 B J U I N T E R N A T I O N A L
AUTUMN 2012 PARKING AT N.G.H We have received on good authority that the N.G.H. are now employing a private firm to ‘manage’ the car parks. The good news is that on October 1st it became illegal for firms to clamp vehicles on private property. The bad news is that people, like the NGH, are getting private firms to put parking tickets on cars parked without a correct ticket and th
CONGESTIVE HEART FAILURE AND PUBLIC HEALTH Outline of Chapter 4. Types and causes 5. Common symptoms and signs 6. Diagnosis 7. Classes and stages of heart failure 8. Treatment 9. Lifestyle 10. Heart failure in minorities 11. Cardiac rehabilitation programs 12. Public policy 13. Beneficial websites 14. References 1- Definition Heart failure (HF) is a chronic disease characterized by